IP Library › Granted Patent US 9,957,565
Granted Patent B2
US 9,957,565 · App. 13/377,216 · Granted May 1, 2018

Method for detecting polymorphisms

Inventors: Eduardo Salas Pérez-Rasilla (Barcelona, ES); Jaume Marrugat De La Iglesia (Barcelona, ES); Roberto Elosua Llanos (Barcelona, ES); Sergio Castillo Fernandez (Barcelona, ES); Joan Salgado Gómez (Barcelona, ES); Jose Maria Ordovás Munoz (Barcelona, ES)
Assignee: Gendiag.exe, S.L.
C12Q1/6883C12Q2600/156
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,957,565
App. No.
13/377,216
Granted
May 1, 2018
Kind
B2
Abstract

The invention relates to a method for determining the risk of suffering a cardiovascular disease based on the presence of different polymorphisms as well as to kits for practicing the above method. The invention also relates to a method for determining the risk of suffering a cardiovascular disease by combining the absence or presence of one or more polymorphic markers in a sample from the subject with conventional risk factors for CVD as well as computer-implemented means for carrying out said method.

Claims (11)

1. A method of detecting polymorphisms in a biological sample, comprising

(a1) assaying the biological sample isolated from a human subject for the presence of polymorphisms at position 27 within each of the nucleic acid sequences of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10 by direct sequencing of nucleic acids in the sample;

or

(a2) assaying the biological sample isolated from a human subject for the presence of polymorphisms at position 27 within each of the nucleic acid sequences of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10 by detecting hybridization or lack of hybridization of the nucleic acid sequences of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10 in the biological sample with the set of nucleic acid probes; and

(b) detecting polymorphisms in the biological sample at position 27 within the nucleic acid sequences of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10 based on the sequencing in (a1) or detecting hybridization or lack of hybridization in (a2);

wherein the polymorphism at position 27 within the nucleic acid sequences of SEQ ID NOs:1, 3 and 7-10 is a C in SEQ ID NO:1, C in SEQ ID NO:3, T in SEQ ID NO:7, C in SEQ ID NO:8, C in SEQ ID NO:9, and T in SEQ ID NO:10.

2. The method according to claim 1 , further comprising determining one or more of age, race, sex, body mass index, blood pressure, smoking status, low density lipoprotein (LDL)- or high density lipoprotein (HDL)-cholesterol level, systolic blood pressure, diastolic blood pressure, history of heart failure, diabetes, renal insufficiency, left ventricular hypertrophy, alcohol consumption history, smoking history, exercise history, diet, and family history of cardiovascular disease or disorder of the human subject.

3. The method according to claim 1 , wherein the sample is an oral tissue sample, scraping, or wash, a biological fluid sample, saliva, urine or blood.

4. The method according to claim 1 , further comprising amplifying nucleic acids in the sample, wherein the presence or absence of the polymorphisms is identified by amplifying or failing to amplify an amplification product from the sample, wherein the amplification product is preferably digested with a restriction enzyme before analysis and/or wherein the polymorphisms are identified by hybridizing the nucleic acid sample with a primer label which is a detectable moiety.

5. The method according to claim 1 , wherein the method comprises assaying the biological sample for the presence of polymorphisms at position 27 within each of the nucleic acid sequences of SEQ ID NO:1 to 11.

6. The method according to claim 5 , wherein said polymorphisms at said positions 27 are selected from the group of C in SEQ ID NO:1, A in SEQ ID NO:2, C in SEQ ID NO:3, T in SEQ ID NO:4, C in SEQ ID NO:5, A in SEQ ID NO:6, T in SEQ ID NO:7, C in SEQ ID NO:8, C in SEQ ID NO:9, T in SEQ ID NO:10 and T in SEQ ID NO:11.

Assignments (4)
CHANGE OF NAME Recorded Nov 10, 2021
From: GENINCODE UK, LTD.
To: GENINCODE LIMITED
Reel/Frame 058067/0612 →
CHANGE OF NAME Recorded Nov 10, 2021
From: GENINCODE LIMITED
To: GENINCODE PLC
Reel/Frame 058086/0302 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2020
From: GENDIAG.EXE. S.L.
To: GENINCODE UK, LTD.
Reel/Frame 054220/0810 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 23, 2012
From: PEREZ-RASILLA, EDUARDO SALAS; GOMEZ, JOAN SALGADO; FERNANDEZ, SERGIO CASTILLO; LLANOS, ROBERTO ELOSUA; ORDOVAS MUNOZ, JOSE MARIA; DE LA IGLESIA, JAUME MARRUGAT
To: GENDIAG.EXE, S.L.
Reel/Frame 027749/0771 →
Priority Claims (1)
EP 09162329 · Jun 9, 2009 · regional
Continuity (1)
Related Publication 20120141450A1 · Jun 7, 2012